Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 1, 13, 37, 23, 84, 23 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction
2. Chronic Obstructive Pulmonary Disease (COPD) - Overview
3. Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
4. Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
5. Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
6. Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
7. Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
8. Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
9. Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/hdl4n5/chronic?w=4